Investor First Manhattan Issues Update to VIVUS Shareholders

First Manhattan Co. (“FMC”), an owner-managed and operated investment advisory firm and the owner of approximately 9.9 percent of the outstanding shares of VIVUS, Inc. (“Vivus”)

, today urged Vivus shareholders to consider three key facts as they make the important choice that will determine the future of their investment in Vivus. Fact I: The centralized procedure is the best pathway for Qsymia's E.U. approval Vivus originally attempted to gain E.U. approval through the centralized procedure, but it failed. The centralized procedure is currently the only pathway that large pharma uses for E.U. approval of blockbuster drugs according to FMC's consultants. The primary reason for choosing